Core Viewpoint - The stock of药捷安康-B (02617) experienced a significant decline, dropping over 11% during trading, with a current decrease of 9.74% to HKD 176.2, and a trading volume of HKD 591 million. The company announced plans to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, representing approximately 11.33% of the total issued shares, pending regulatory approvals [1][1][1]. Group 1 - The company’s stock price fell sharply, with a notable drop of over 11% during trading hours [1] - As of the latest update, the stock is down 9.74%, trading at HKD 176.2, with a total transaction volume of HKD 591 million [1] - The board has approved an application to the China Securities Regulatory Commission for the conversion of domestic shares into H-shares, which will be eligible for listing and trading on the main board of the Hong Kong Stock Exchange [1][1][1] Group 2 - The stock had a strong rebound from October 16 to 17, with a cumulative increase of nearly 80% over two days [1] - The rebound was characterized as a violent surge driven by international short-term speculative funds, which were utilized by domestic major funds as an "exit window" [1] - The largest holding group did not participate in the buying but instead became the largest seller, indicating that the foundation of this rebound was weakened and reliant on subsequent speculative inflows [1][1][1]
港股异动 | 药捷安康-B(02617)盘中跌超11% 公司拟H股全流通 占已发行股份总数约1...